[1]姚瑶,郑仁东,刘超.血浆置换治疗甲状腺功能亢进症的研究进展[J].国际内分泌代谢杂志,2020,40(05):320-322.[doi:10.3760/cma.j.cn121383-20191218-12047]
 Yao Yao,Zheng Rendong,Liu Chao.Update on plasmapheresis for hyperthyroidism[J].International Journal of Endocrinology and Metabolism,2020,40(05):320-322.[doi:10.3760/cma.j.cn121383-20191218-12047]
点击复制

血浆置换治疗甲状腺功能亢进症的研究进展()
分享到:

《国际内分泌代谢杂志》[ISSN:1673-4157/CN:12-1383/R]

卷:
40
期数:
2020年05期
页码:
320-322
栏目:
综述
出版日期:
2020-09-20

文章信息/Info

Title:
Update on plasmapheresis for hyperthyroidism
作者:
姚瑶郑仁东刘超
南京中医药大学附属中西医结合医院内分泌代谢病院区 210028
Author(s):
Yao Yao Zheng Rendong Liu Chao
Endocrine and Diabetes Center, Jiangsu Province Hospital on Integration of Chinese and Western Medicine, Nanjing University of Traditional Chinese Medicine, Nanjing 210028, China
关键词:
血浆置换 甲状腺功能亢进症 甲状腺毒症
Keywords:
Plasmapheresis Hyperthyroidism Thyrotoxicosis
DOI:
10.3760/cma.j.cn121383-20191218-12047
文献标志码:
A
摘要:
甲状腺功能亢进症(甲亢)是循环中过多的甲状腺激素导致的以高代谢为主要表现的临床综合征,其在全球的发病率逐渐上升。血浆置换是严重甲状腺毒症的有效替代疗法,它通过去除与血浆蛋白结合的大分子物质来快速恢复甲状腺素水平,快速改善临床症状。其在临床上更多地用于治疗严重甲亢、不耐受抗甲状腺药物及甲状腺危象的患者。血浆置换导致的一些相关不良反应,亦需关注。
Abstract:
Hyperthyroidism is a clinical syndrome characterized by hypermetabolism caused by excessive thyroxine in the circulation, and its global incidence is gradually increasing. Plasmapheresis is an effective alternative to severe thyrotoxicosis. It quickly restores the level of thyroxine and improves clinical symptoms by removing macromolecular substances that bind to plasma proteins. Plasmapheresis is more widely used in the treatment of severe hyperthyroidism, patients with intolerance of anti-thyroid drugs and thyroid storm. Some related adverse reactions caused by plasmapheresis should also be concerned.

参考文献/References:

[1] Ba JH, Wu BQ, Wang YH, et al. Therapeutic plasma exchange and continuous renal replacement therapy for severe hyperthyroidism and multi-organ failure:a case report[J]. World J Clin Cases,2019,7(4):500-507.DOI:10.12998/wjcc.v7.i4.500.
[2] Taylor PN, Albrecht D, Scholz A, et al. Global epidemiology of hyperthyroidism and hypothyroidism[J]. Nat Rev Endocrinol,2018, 14(5): 301-316.DOI:10.1038/nrendo.2018.18.
[3] Keklik M, Kaynar L, Yilmaz M, et al. The results of therapeutic plasma exchange in patients with severe hyperthyroidism: a retrospective multicenter study[J]. Transfus Apher Sci, 2013, 48(3): 327-330.DOI:10.1016/j.transci.2013.04.010.
[4] 王平. 甲亢的饮食调理[J]. 食品与健康, 2012,(4):30-31.
[5] Min SH, Phung A, Oh TJ, et al. Therapeutic plasmapheresis enabling radioactive iodine treatment in a patient with thyrotoxicosis[J].J Korean Med Sci,2015,30(10):1531-1534.DOI:10.3346/jkms.2015.30.10.1531.
[6] Simsir IY, Ozdemir M, Duman S, et al. Therapeutic plasmapheresis in thyrotoxic patients[J]. Endocrine,2018, 62(1): 144-148.DOI:10.1007/s12020-018-1661-x.
[7] Garla V, Kovvuru K, Ahuja S, et al. Severe hyperthyroidism complicated by agranulocytosis treated with therapeutic plasma exchange: case report and review of the literature[J]. Case Rep Endocrinol, 2018, 2018: 4135940.DOI:10.1155/2018/4135940.
[8] Malik S, Russman AN, Katramados AM, et al. Moyamoya syndrome associated with Graves' disease:a case report and review of the literature[J]. J Stroke Cerebrovasc Dis, 2011, 20(6):528-536.DOI:10.1016/j.jstrokecerebrovasdis.2010.03.006.
[9] Wyble AJ, Moore SC, Yates SG. Weathering the storm: a case of thyroid storm refractory to conventional treatment benefiting from therapeutic plasma exchange[J]. J Clin Apher,2018,33(6):678-681.DOI:10.1002/jca.21658.
[10] Candoni A, De Marchi F, Vescini F, et al. Graves' disease thyrotoxicosis and propylthiouracil related agranulocytosis successfully treated with therapeutic plasma exchange and G-CSF followed by total thyroidectomy[J]. Mediterr J Hematol Infect Dis, 2017, 9(1): e2017058.DOI:10.4084/MJHID.2017.058.
[11] Muller C, Perrin P, Faller B, et al. Role of plasma exchange in the thyroid storm[J]. Ther Apher Dial,2011, 15(6):522-531.DOI:10.1111/j.1744-9987.2011.01003.x.
[12] Mcgonigle AM, Tobian A, Zink JL, et al. Perfect storm: therapeutic plasma exchange for a patient with thyroid storm[J]. J Clin Apher,2018, 33(1):113-116.DOI:10.1002/jca.21560.
[13] Zhu L, Zainudin SB, Kaushik M, et al. Plasma exchange in the treatment of thyroid storm secondary to type Ⅱ amiodarone-induced thyrotoxicosis[J]. Endocrinol Diabetes Metab Case Rep,2016, 2016: 160039.DOI:10.1530/EDM-16-0039.
[14] Petry J, Van Schil PE, Abrams P, et al. Plasmapheresis as effective treatment for thyrotoxic storm after sleeve pneumonectomy[J]. Ann Thorac Surg, 2004,77(5):1839-1841.DOI:10.1016/S0003-4975(03)01246-3.
[15] Jha S, Waghdhare S, Reddi R, et al. Thyroid storm due to inappropriate administration of a compounded thyroid hormone preparation successfully treated with plasmapheresis[J]. Thyroid, 2012, 22(12):1283-1286.DOI:10.1089/thy.2011.0353.
[16] Lew WH, Chang CJ, Lin JD, et al. Successful preoperative treatment of a Graves' disease patient with agranulocytosis and hemophagocytosis using double filtration plasmapheresis[J]. J Clin Apher,2011, 26(3):159-161.DOI:10.1002/jca.20282.
[17] Koball S, Hickstein H, Gloger M, et al. Treatment of thyrotoxic crisis with plasmapheresis and single pass albumin dialysis: a case report[J]. Artif Organs, 2010, 34(2):E55-E58.DOI:10.1111/j.1525-1594.2009.00924.x.
[18] Lu J, Samson S, Kass J, et al. Acute psychosis in a pregnant patient with Graves' hyperthyroidism and anti-NMDA receptor encephalitis[J]. BMJ Case Rep, 2015, 2015.DOI:10.1136/bcr-2014-208052.
[19] Fu H, Cheng L, Jin Y, et al. Thyrotoxicosis with concomitant thyroid cancer[J]. Endocr Relat Cancer,2019.DOI:10.1530/ERC-19-0129.
[20] Miljic D, Stojanovic M, Jesic R, et al. Role of plasma exchange in autoimmune hyperthyroidism complicated by severe tiamazol-induced cholestatic jaundice[J]. Transfus Apher Sci, 2013, 49(2):354-356.DOI:10.1016/j.transci.2013.05.007.

相似文献/References:

[1]朱丹,陈国芳,刘超,等.糖尿病患者合并甲状腺功能异常的机制 及其影响[J].国际内分泌代谢杂志,2016,36(03):206.[doi:10.3760/cma.j.issn.1673-4157.2016.03.16]
 Zhu Dan*,Chen Guofang,Liu Chao,et al.Mechanisms of diabetes combined with thyroid dysfunction and its influence[J].International Journal of Endocrinology and Metabolism,2016,36(05):206.[doi:10.3760/cma.j.issn.1673-4157.2016.03.16]
[2]韩煦,魏军平.促甲状腺激素受体抗体的检测及其在Graves病 诊疗中的价值[J].国际内分泌代谢杂志,2017,37(02):94.[doi:10.3760/cma.j.issn.1673-4157.2017.02.006]
 Han Xu,Wei Junping..Thyroid stimulating hormone receptor antibodies assays and its clinical significance in Graves' disease[J].International Journal of Endocrinology and Metabolism,2017,37(05):94.[doi:10.3760/cma.j.issn.1673-4157.2017.02.006]
[3]朱萍,卫红艳,王坤玲,等.Graves病甲状腺功能亢进症性肝损害的 相关因素分析[J].国际内分泌代谢杂志,2017,37(03):164.[doi:10.3760/cma.j.issn.1673-4157.2017.03.005]
 Zhu Ping,Wei Hongyan,Wang Kunling,et al.Related factors of hyperthyroidism-related liver dysfunction in Graves' disease[J].International Journal of Endocrinology and Metabolism,2017,37(05):164.[doi:10.3760/cma.j.issn.1673-4157.2017.03.005]
[4]刘燕晶 张帆.甲状腺功能亢进症性肝损害的发生机制[J].国际内分泌代谢杂志,2019,39(01):34.[doi:10.3760/cma.j.issn.1673-4157.2019.01.008]
 Liu Yanjing,Zhang Fan.The pathogenesis of liver damage of hyperthyroidism[J].International Journal of Endocrinology and Metabolism,2019,39(05):34.[doi:10.3760/cma.j.issn.1673-4157.2019.01.008]
[5]刘天琪,张秀英,纪立农.促甲状腺激素受体抗体的检测及应用进展[J].国际内分泌代谢杂志,2021,41(01):5.[doi:10.3760/cma.j.cn121383-20200608-06021]
 Liu Tianqi,Zhang Xiuying,Ji Linong..Progression of assay and clinical practice of thyroid stimulating hormone receptor antibody[J].International Journal of Endocrinology and Metabolism,2021,41(05):5.[doi:10.3760/cma.j.cn121383-20200608-06021]
[6]朱航毅,赵一璟,史雨清,等.碳酸锂致肾性尿崩症的研究进展[J].国际内分泌代谢杂志,2022,42(06):485.[doi:10.3760/cma.j.cn121383-20210530-05078]
 Zhu Hangyi,Zhao Yijing,Shi Yuqing,et al.Research progress of nephrogenic diabetes insipidus induced by carbonate lithium[J].International Journal of Endocrinology and Metabolism,2022,42(05):485.[doi:10.3760/cma.j.cn121383-20210530-05078]

更新日期/Last Update: 2020-09-20